The distribution and drug susceptibilities of clinical Candida species in TSARY 2014

Zhou, Zi-Li; Lin, Chung-Cherng; Chu, Wen-Li; Yang, Yun-Liang; Lo, Hsiu‐Jung

doi:10.1016/j.diagmicrobio.2016.09.009

Cited by 19 publications

(7 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The previously observed species shift toward infections by non-albicans species and particularly toward C. glabrata infections continued over the years 2012 to 2015. This trend has been observed in several population-based candidemia surveys (3,12,13,20,50). The increase in the proportion of C. glabrata infections has happened concomitantly with an increase in azole use in Denmark and with the population getting older.…”

Section: Discussionmentioning

confidence: 67%

“…Besides increasing incidence rates, another common observation is the changing species distribution to non-albicans species and particularly to Candida glabrata in the Northern Hemisphere, Australia, and Taiwan and C. parapsilosis in southern Europe and South America (3,12,13,19,20) at the expense of C. albicans. The increase in C. glabrata levels has been coupled with an increased use of azoles, to which C. glabrata is intrinsically less susceptible (18,21,22).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Update from a 12-Year Nationwide Fungemia Surveillance: Increasing Intrinsic and Acquired Resistance Causes Concern

et al. 2018

View full text Add to dashboard Cite

New data from the years 2012 to 2015 from the Danish National Fungemia Surveillance are reported, and epidemiological trends are investigated in a 12-year perspective (2004 to 2015). During 2012 to 2015, 1,900 of 1,939 (98%) fungal bloodstream isolates were included. The average incidence was 8.4/100,000 inhabitants, and this appears to represent a stabilizing trend after the increase to 10.1/100,000 in 2011. The incidence was higher in males than females (10.0 versus 6.8) and in patients above 50 years, and those changes were mainly driven by an increasing incidence among 80-to-89-year-old males (65.3/100,000 in 2014 to 2015). The proportion of isolates decreased from 2004 to 2015 (64.4% to 42.4%) in parallel with a doubling of the proportion of isolates (16.5% to 34.6%, < 0.0001). was more common among females (34.0% versus 30.4% in males). Following an increase in 2004 to 2011, the annual drug use stabilized during the last 2 to 3 years of that time period but remained higher than in other Nordic countries. This was particularly true for the fluconazole and itraconazole use in the primary health care sector, which exceeded the combined national levels of use of these compounds in each of the other Nordic countries. Fluconazole susceptibility decreased (68.5%, 65.2%, and 60.6% in 2004 to 2007, 2008 to 2011, and 2012 to 2015, respectively, < 0.0001), and echinocandin resistance emerged in (0%, 0.6%, and 1.7%, respectively, < 0.001). Amphotericin B susceptibility remained high (98.7%). Among 16 (2.7%) echinocandin-resistant isolates (2012 to 2015), 13 harbored FKS mutations and 5 (31%) were multidrug resistant. The epidemiological changes and the increased incidence of intrinsic and acquired resistance emphasize the importance of continued surveillance and of strengthened focus on antifungal stewardship.

show abstract

Section: Discussionmentioning

confidence: 67%

mentioning

confidence: 99%

Update from a 12-Year Nationwide Fungemia Surveillance: Increasing Intrinsic and Acquired Resistance Causes Concern

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Although breakthrough to anidulafungin C. parapsilosis fungaemia has been sporadically reported, anidulafungin resistance in C. parapsilosis remains uncommon . In the most recently published SENTRY surveillance study, no anidulafungin‐resistant C. parapsilosis isolates were reported .…”

Section: Discussionmentioning

confidence: 99%

Anidulafungin for the treatment of candidaemia caused byCandida parapsilosis: Analysis of pooled data from six prospective clinical studies

Kontoyiannis

Bassetti

Nucci

et al. 2017

Mycoses

View full text Add to dashboard Cite

Summary Concerns with echinocandin use for infections caused by Candida parapsilosis complex species have driven the need for data to support echinocandin clinical efficacy in such patients. Data from six prospective studies were pooled to assess efficacy and safety of anidulafungin in patients with candidaemia caused by C. parapsilosis. Patient‐level data were pooled from patients with microbiologically confirmed candidaemia due to C. parapsilosis treated with anidulafungin. Patients received a 200 mg intravenous (IV) loading dose of anidulafungin (day 1) and 100 mg daily thereafter. IV treatment could be switched to oral azole therapy after ≥5 or ≥10 days. Primary endpoint was global response at end of IV therapy (EOIVT). Seventy patients had candidaemia caused by C. parapsilosis. Global response was 77.1% (95% CI: 67.3, 87.0) at EOIVT and 70.0% (95% CI: 59.3, 80.7) at end of treatment. Three of 55 isolates (with MICs available) were resistant to anidulafungin (MIC ≥8 mg/L). All‐cause mortality was 5.7% (n=4/70) by day 14 and 14.3% (n=10/70) by day 28. IV anidulafungin was effective for the treatment of C. parapsilosis candidaemia in this population, consistent with efficacy previously demonstrated for other Candida species. (ClinicalTrials.gov identifiers: NCT00496197, NCT00548262, NCT00537329, NCT00689338, NCT00806351, NCT00805740).

show abstract

“…tested (Figure 3C). C. albicans is responsible for the majority of Candida infections; however, infections by other less drug-susceptible Candida species have become more common recently [6,30]. Among them, C. tropicalis is predominantly identified in patients with leukemia and neutropenia [7,31].…”

Section: Discussionmentioning

confidence: 99%

Generation and Characterization of Single Chain Variable Fragment against Alpha-Enolase of Candida albicans

Leu

Lee

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

Candida albicans (C. albicans) is an opportunistic human pathogen responsible for approximately a half of clinical candidemia. The emerging Candida spp. with resistance to azoles is a major challenge in clinic, suggesting an urgent demand for new drugs and therapeutic strategies. Alpha–enolase (Eno1) is a multifunctional protein and represents an important marker for invasive candidiasis. Thus, C. albicans Eno1 (CaEno1) is believed to be an important target for the development of therapeutic agents and antibody drugs. Recombinant CaEno1 (rCaEno1) was first used to immunize chickens. Subsequently, we used phage display technology to construct two single chain variable fragment (scFv) antibody libraries. A novel biopanning procedure was carried out to screen anti-rCaEno1 scFv antibodies, whose specificities were further characterized. The polyclonal IgY antibodies showed binding to rCaEno1 and native CaEno1. A dominant scFv (CaS1) and its properties were further characterized. CaS1 attenuated the growth of C. albicans and inhibited the binding of CaEno1 to plasminogen. Animal studies showed that CaS1 prolonged the survival rate of mice and zebrafish with candidiasis. The fungal burden in kidney and spleen, as well as level of inflammatory cytokines were significantly reduced in CaS1-treated mice. These results suggest CaS1 has potential of being immunotherapeutic drug against C. albicans infections.

show abstract

The distribution and drug susceptibilities of clinical Candida species in TSARY 2014

Cited by 19 publications

References 56 publications

Update from a 12-Year Nationwide Fungemia Surveillance: Increasing Intrinsic and Acquired Resistance Causes Concern

Update from a 12-Year Nationwide Fungemia Surveillance: Increasing Intrinsic and Acquired Resistance Causes Concern

Anidulafungin for the treatment of candidaemia caused byCandida parapsilosis: Analysis of pooled data from six prospective clinical studies

Generation and Characterization of Single Chain Variable Fragment against Alpha-Enolase of Candida albicans

Contact Info

Product

Resources

About